Previous close | 14.90 |
Open | 14.85 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 14.70 - 15.04 |
52-week range | 12.98 - 21.43 |
Volume | |
Avg. volume | 6,392 |
Market cap | N/A |
Beta (5Y monthly) | 0.94 |
PE ratio (TTM) | 31.85 |
EPS (TTM) | 0.47 |
Earnings date | 26 Aug 2024 - 30 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
As global markets navigate through a period of relative calm with anticipation for upcoming earnings reports and key economic indicators, investors continue to assess the landscape for robust investment opportunities. In this environment, growth companies with high insider ownership can be particularly compelling, as substantial insider stakes often signal confidence in the company's future prospects from those who know it best.
Preclinical models show benefit of afamelanotide as MC1R therapy in Parkinson’s DiseaseMELBOURNE, Australia, June 18, 2024 (GLOBE NEWSWIRE) -- CLINUVEL today announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease (PD or Parkinson’s) in fair-skinned patients. The program objectives are to determine whether afamelanotide – through melanocortin-1 receptor (MC1R) activation – is able to lower α-synuclein (a toxin) in blood levels in PD patients,
Key Insights The considerable ownership by retail investors in Clinuvel Pharmaceuticals indicates that they...